Evidence map›Paper›PMID 40332529›Full record

ArticleInternational journal of molecular sciences2025

VEGF in Tears as a Biomarker for Exudative Age-Related Macular Degeneration: Molecular Dynamics in a Mouse Model and Human Samples.

Seyed Mohamad Mehdi Moshtaghion, Filippo Locri, Alvaro Plaza Reyes, Flavia Plastino, Anders Kvanta, Maria Jose Morillo-Sanchez, Enrique Rodríguez-de-la-Rúa, Estanislao Gutierrez-Sanchez, Adoración Montero-Sánchez, Helena Lucena-Padros and 2 more

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Seyed Mohamad Mehdi MoshtaghionDepartment of Integrative Pathophysiology and Therapies, Andalusian Molecular Biology and Regenerative Medicine Centre (CABIMER), Junta de Andalucía, CSIC, University of Seville, University Pablo de Olavide, 41092 Seville, Spain.ORCID 0000-0002-6039-4246
Filippo LocriDepartment of Clinical Neuroscience, Division of Eye and Vision, St. Erik Eye Hospital, Karolinska Institutet, 17177 Stockholm, Sweden.ORCID 0009-0000-3772-8730
Alvaro Plaza ReyesDepartment of Integrative Pathophysiology and Therapies, Andalusian Molecular Biology and Regenerative Medicine Centre (CABIMER), Junta de Andalucía, CSIC, University of Seville, University Pablo de Olavide, 41092 Seville, Spain.ORCID 0000-0003-1167-6316
Flavia PlastinoDepartment of Clinical Neuroscience, Division of Eye and Vision, St. Erik Eye Hospital, Karolinska Institutet, 17177 Stockholm, Sweden.
Anders KvantaDepartment of Clinical Neuroscience, Division of Eye and Vision, St. Erik Eye Hospital, Karolinska Institutet, 17177 Stockholm, Sweden.ORCID 0000-0003-2194-7490
Maria Jose Morillo-SanchezDepartment of Ophthalmology, Virgen Macarena University Hospital, 41009 Seville, Spain.
Enrique Rodríguez-de-la-RúaDepartment of Ophthalmology, Virgen Macarena University Hospital, 41009 Seville, Spain.
Estanislao Gutierrez-SanchezDepartment of Ophthalmology, Virgen Macarena University Hospital, 41009 Seville, Spain.ORCID 0000-0003-4851-680X
Adoración Montero-SánchezDepartment of Integrative Pathophysiology and Therapies, Andalusian Molecular Biology and Regenerative Medicine Centre (CABIMER), Junta de Andalucía, CSIC, University of Seville, University Pablo de Olavide, 41092 Seville, Spain.
Helena Lucena-PadrosDepartment of Maternofetal Medicine, Genetics and Reproduction, Institute of Biomedicine of Seville, CSIC, Virgen del Rocio University Hospital, University of Seville, 41013 Seville, Spain.ORCID 0000-0001-7569-3663
Helder AndréDepartment of Clinical Neuroscience, Division of Eye and Vision, St. Erik Eye Hospital, Karolinska Institutet, 17177 Stockholm, Sweden.ORCID 0000-0002-2926-2376
Francisco J Díaz-CorralesDepartment of Integrative Pathophysiology and Therapies, Andalusian Molecular Biology and Regenerative Medicine Centre (CABIMER), Junta de Andalucía, CSIC, University of Seville, University Pablo de Olavide, 41092 Seville, Spain.ORCID 0000-0002-5752-0205

Funding

Instituto de Salud Carlos III and the Fondo Europeo de Desarrollo Regional PI17/01026, P-FIS: 21/00087Junta de Andalucía, Programa Nicolás Monardes C2-0009-2020
6 · The paper itself

Abstract

Vascular endothelial growth factor (VEGF) is a key mediator of exudative age-related macular degeneration (eAMD), yet non-invasive biomarkers for disease monitoring remain limited. This study evaluates VEGF levels in human tear fluid as a potential biomarker for eAMD and investigates the molecular dynamics of VEGF in a laser-induced choroidal neovascularization (lCNV) mouse model. Tear VEGF levels were quantified using proximity qPCR immunoassays in eAMD patients (n = 29) and healthy controls (n = 21) and correlated with optical coherence tomography (OCT) findings. Molecular analyses, including immunohistochemistry, gene expression profiling, and phosphorylation assays, were conducted on choroid-retinal pigment epithelium (RPE) and lacrimal gland (LG) tissues from lCNV mice (n = 25). Tear VEGF levels were significantly elevated in eAMD patients, correlating with disease severity. Females exhibited higher VEGF levels, a pattern not replicated in the mouse model. In lCNV mice, VEGF overexpression originated from the choroid-RPE, driven by hypoxic and inflammatory signaling, with no significant LG contribution. Increased VEGF, IL-6, and vimentin expression, along with NF-κB and STAT3 activation, were observed. These findings suggest that tear VEGF is a promising non-invasive biomarker for eAMD, warranting further validation for clinical application in disease monitoring and treatment optimization.

Indexed as

Macular DegenerationTearsVascular Endothelial Growth Factor AAgedAged, 80 and overAnimalsBiomarkersChoroidChoroidal NeovascularizationDisease Models, AnimalFemaleHumansMaleMiceMiddle AgedNF-kappa BBiomarkersNF-kappa BSTAT3 Transcription FactorVascular Endothelial Growth Factor AVEGFA protein, humanage-related macular degenerationbiomarkerchoroidal neovascularizationtear fluidvascular endothelial growth factor

Identifiers

PMID40332529
PMCPMC12027898

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.